Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval

By: Benzinga via Benzinga

August 07, 2017 at 11:56 AM EDT

Morgan Stanley reduced its price target on the shares of Mylan N.V. (NASDAQ: MYL) following downward revision to its estimates due to ...

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.